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M. S. Hasan,*1 P. L. Ryan,†1
L. A. Bergmeier * and F. Fortune*
*Centre for Clinical and Diagnostic Oral
Sciences, and †Centre for Adult Oral Health,
Institute of Dentistry, Barts and The London
School of Medicine and Dentistry, Queen Mary
University of London, London, UK
Accepted for publication 31 January 2017
Correspondence: F. Fortune, Centre for
Clinical and Diagnostic Oral Sciences,
Institute of Dentistry, Blizard Building, 4
Newark Street, Barts and The London School
of Medicine and Dentistry, Queen Mary




Behçet’s disease (BD) is an autoinflammatory, chronic relapsing/remitting
disease of unknown aetiology with both innate and acquired immune cells
implicated in disease pathogenesis. Peripheral blood natural killer (NK) cells
and their CD56Dim/CD56Bright subsets were surface phenotyped using CD27
and CD16 surface markers in 60 BD patients compared to 60 healthy
controls (HCs). Functional potential was assessed by production of
interferon (IFN)-g, granzyme B, perforin and the expression of
degranulation marker CD107a. The effects of disease activity (BDActive
versus BDQuiet) and BD medication on NK cells were also investigated.
Peripheral blood NK cells (P< 00001) and their constituent CD56Dim
(P< 00001) and CD56Bright (P 5 00015) subsets were depleted significantly
in BD patients compared to HCs, and especially in those with active disease
(BDActive) (P< 00001). BD patients taking azathioprine also had
significantly depleted NK cells compared to HCs (P< 00001). A stepwise
multivariate linear regression model confirmed BD activity and azathioprine
therapy as significant independent predictor variables of peripheral blood
NK percentage (P< 0001). In general, CD56Dim cells produced more
perforin (P< 00001) and granzyme B (P< 001) expressed higher CD16
levels (P< 00001) compared to CD56Bright cells, confirming their increased
cytotoxic potential with overall higher NK cell CD107a expression in BD
compared to HCs (P< 001). Interestingly, IFN-g production and CD27
expression were not significantly different between CD56Dim/CD56Bright
subsets. In conclusion, both BD activity and azathioprine therapy have
significant independent depletive effects on the peripheral blood NK cell
compartment.
Keywords: Behçet’s disease, immunopathology, immunotherapies and
innate immunity, NK cells
Introduction
Behçet’s disease (BD) is a chronic relapsing/remitting multi-
system disease of poorly understood aetiology, characterized
primarily by orogenital ulceration, but also affecting other
body systems, including the eye (uveitis), joints (arthritis)
and skin [1,2]. BD can be life-threatening in severe forms
where the disease progresses to involve the large blood ves-
sels, central nervous system or the gastrointestinal tract. The
disease is increased approximately sixfold in patients with
human leucocyte antigen (HLA)-B51/B5 genetic polymor-
phisms [3] and is regarded widely as an autoinflammatory
condition, although autoimmune responses to certain spe-
cific antigens have been described in the disease [4,5]. Viral
infection with Epstein–Barr virus (EBV) and herpes simplex
virus (HSV) were also thought to be important in both the
initiation and in triggering acute exacerbations of affected
systems in BD [6,7] and natural killer (NK) cells are impor-
tant in controlling viral infections.
Loss of normal immune regulation is thought to play a
key role in BD pathology, with neutrophil activation and
recruitment to the site of inflammatory lesions thought to
be central in the disease process [8,9]. Additionally, T helper
VC 2017 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 188: 311–322
311
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12939
type 1 (Th1)/Th17 cytokine polarization of CD41 T cells is
a consistent finding in disease lesions and in peripheral
blood where increased interferon (IFN)-g, tumour necrosis
factor (TNF)-a, interleukin (IL)-8 and IL-17 levels have
been correlated with BD activity [10]. Conversely, a reduc-
tion in the regulatory T cells (Tregs) and the cytokine IL-10
has also been described in the disease [11,12]. While BD
lesions are predominated by neutrophils and CD41 T cells,
innate lymphoid cells including gd T cells and conventional
NK cells are also found in BD lesions, and may play a signifi-
cant role in driving the CD41 Th1 response characteristic of
BD lesions [13,14].
NK cells are CD3– granular cytotoxic lymphocytes
included in the type 1 group of innate lymphoid cells with
the ability to mount cytotoxic major histocompatibility
complex (MHC)-unrestricted responses against pathogens
without prior antigen priming [15–17]. They have been
characterized conventionally using CD56 [neural cell adhe-
sion molecule (NCAM)], dividing them into the predomi-
nant CD56Dim subset (approximately 90% in peripheral
blood) and the minority CD56Bright subset [18]. These sub-
sets are both phenotypically and functionally distinct, with
the more cytotoxic CD56Dim NK subset displaying
increased potential to produce perforin and granzyme B
[19,20]. This is in contrast to the CD56Bright NK subset,
which is less cytotoxic and is more immunoregulatory in
function, with a propensity to produce significantly more
IFN-g and TNF-a [21]. Two further surface markers that
have been used commonly to characterize NK cells and
their subsets are the low-affinity Fc-receptor, CD16 and the
TNF-receptor co-stimulatory surface molecule CD27
[22,23]. In general, CD56Dim NK cells have higher CD16
expression reflective of their more cytotoxic function, with
CD27 expression found mainly on the immunoregulatory,
cytokine-producing CD56Bright subset [23–25]. Peripheral
blood circulatory NK cells contain high concentrations of
preformed cytotoxic granules (e.g. granzyme B and per-
forin) in their cytoplasm, which can be used to kill target
cells on degranulation into the immunological synapse
[26]. The marker CD107a (lysosome-associated membrane
protein) lines the internal surface of cytotoxic granules and
is externalized to the cell surface upon degranulation,
where lysosomes fuse with the cell surface in cytotoxic
lymphocytes [27]. CD107a expression correlates well with
IFN-g and TNF-a cytokine secretion as well as NK cell-
mediated lysis of target cells, and is considered as a more
sensitive marker than intracellular cytokine assays or the
chromium release assay [28,29].
NK cell numbers and activity have been reported previ-
ously in BD with respect to disease activity and also to the
medication used to treat BD patients, e.g. azathioprine,
cyclosporin and corticosteroids [30]. The numbers and cyto-
toxic capacity of NK cells reported in BD lesions appear to
be variable [14,31–36], with uncertainty in the literature due
to the use of different markers to phenotype NK cells and
their subsets [22,23,37]. Several studies have found increased
NK cell numbers in the peripheral blood of BD patients
[14,32], especially during the active phases of disease [38],
while other studies have revealed that BD and matched
healthy controls had similar NK cell numbers in peripheral
blood [31,35,39]. However, there is no previous study, to
our knowledge, reporting on the proportion and functional
potential of NK subsets CD56Dim and CD56Bright in BD.
Another recent study in uveitis-affected BD patients demon-
strates that NK cell cytokine production favours Th1/NK1
cytokine production (TNF-a, IFN-g and IL-2) during peri-
ods of activity, with a relative switch towards Th2/NK2 cyto-
kines (IL-4 and IL-10) during remission [40].
Therefore, this study investigated peripheral blood NK
cells and their CD56Dim and CD56Bright subsets in a large
cohort of BD patients compared to healthy controls. Sub-
sets were characterized further by surface expression of
CD27 and CD16. Functional potential was assessed by pro-
duction of IFN-g, perforin and granzyme B, with degranu-
lation potential assessed using CD107a. Finally, the effect
of various systemic BD medication on the frequency of NK
cells was also investigated.
Materials and methods
Patients and healthy control cohorts
Peripheral blood was obtained from a BD patient cohort
(n 5 60; 20 males, 40 females; median age 5 42 years;
range 5 18–74 years) and compared to healthy controls
(HCs) (n 5 60; 29 males, 31 females; median age 5 33 years,
range 5 21–69 years). All the patients fulfilled the Interna-
tional Study Group for Behçet’s disease criteria (ISG 1990)
[41]. At the time of peripheral blood sampling, the patients
had various degrees of clinical disease activity. For the pur-
poses of this study, BD activity was determined by the pres-
ence (BDActive, n 5 44) or absence (BDQuiet, n 5 16) of any
single clinically active system, including: oral aphthous or
genital ulceration, skin lesions, ocular, vascular, rheumato-
logical, gastrointestinal or neurological involvement on the
day of sampling. In addition, the patient’s current systemic
BD medication was recorded (Table 1). The patient cohort
was recruited from those attending the Behçet’s Centre of
Excellence at The Royal London Hospital (Barts Health
NHS Trust). Peripheral blood samples and associated clinical
information was collected with informed consent from BD
patients and healthy controls. The study was approved by
the East London and the City Local Research Ethics Com-
mittee in full compliance with the Helsinki Declaration
(REC References: P/03/122 and 13/LO/0548).
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll-Paque (GE Healthcare, Amersham, UK) density
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gradient centrifugation. Peripheral blood was layered onto
Ficoll-Paque and centrifuged at 400 g (brake-off) for 35
min at 208C. The interface containing mononuclear cells
was collected and washed in complete media (RPMI-1640;
Lonza, Slough, UK) containing 10% fetal bovine serum
(FBS), 2 mM L-glutamine, penicillin (100 IU/ml) (GIBCO,
Life Technologies, Paisley UK) and streptomycin (100 mg/
ml) (Sigma-Aldrich, Poole, UK) prior to experimental
processing and analysis
Flow cytometry
Fluorochrome-conjugated antibodies specific for the follow-
ing cell surface and intracellular molecules were used: CD3
(HIT3a), CD16 (3G8), CD27 (O323), CD28 (CD28.2), CD56
(HCD56), CD107a (H4A3), granzyme B (GB11), IFN-g
(4S.B3), perforin (dG9) and Vd2 (B6) (antibody reagents
were purchased from either Becton, Dickinson and Com-
pany, Oxford, UK, eBioscience, Lutterworth UK or Biole-
gend, London, UK). PBMCs were incubated on ice with
fluorochrome-conjugated antibodies diluted in fluorescence
activated cell sorter (FACS) buffer [phosphate-buffered saline
(PBS) supplemented with 2% FBS and 5 mM ethylenedia-
mine tetraacetic acid (EDTA) (Gibco, Life Technologies) for
cell surface staining. Cells were subsequently washed and
resuspended in FACS buffer prior to analysis. For intracellu-
lar cytokine staining, PBMCs were stimulated with 50 ng/ml
phorbol 12-myristate 13-acetate (PMA) (Sigma, Poole, UK)
and 1 lg/ml ionomycin (Sigma) for 5 h at 378C; 10 ll brefel-
din A (eBioscience) and 2 lM monensin (eBioscience) were
added during the last 2 h. Cells were stained for cell surface
markers, fixed with IC fixation buffer (eBioscience) for 15
min on ice, and subsequently permeabilized and stained with
intracellular cytokine-specific antibodies diluted in perme-
abilization buffer (eBioscience). Flow cytometry was carried
out using a FACS Canto II flow cytometer (BD Biosciences)
and data were analysed using FlowJo software (Tree Star, Inc.,
Ashland, OR, USA). NK cells were defined as
CD3–Vd2–CD561, subdivided into CD56Dim and CD56Bright
subsets and expressed relative to total gated lymphocytes.





















Gender (M : F) 29 M, 31 F 6 M, 10 F 14 M, 30 F 20 M, 40 F
No. of systems with BD activity 0 0 1 system (n 5 16)
2 systems (n 5 6)
3 systems (n 5 15)
4 systems n 5 5)
5 systems (n 5 1)
6 systems (n 5 1)
BD medication (total no. of
patients on each BD-associated
systemic therapy)
n.a Aza 5 5 Aza 5 14 Aza 5 19
Col 5 5 Col 5 9 Col 5 14
Pred 5 4 Pred 5 12 Pred 5 16
MMF 5 3 MMF 5 3 MMF 5 6
*Inf 5 1 Inf 5 0 Inf 5 1
*Met 5 0 Met 5 1 Met 5 1
No BD meds 5 2 No BD meds 5 16 No BD meds 5 18
BD medication combinations n.a. Aza only 5 2 Aza only 5 6 Aza only 5 8
Col only 5 4 Col only 5 5 Col only 5 9
MMF only 5 2 MMF only 5 1 MMF only 5 3
Pred only 5 1 Pred only 5 4 Pred only 5 5
Inf only 5 1 Inf only 5 0 Inf only 5 1
Aza1Col 5 1 Aza1Col 5 3 Aza1Col 5 4
Aza1Pred 5 2 Aza1Pred 5 4 Aza1Pred 5 6
MMF1Pred 5 1 MMF1Pred 5 2 MMF1Pred 5 3
Pred1Met 5 0 Pred1Met 5 1 Pred1Met 5 1
Aza1Pred1Col 5 0 Aza1Pred1Col 5 1 Aza1Pred1Col 5 1
No BD meds 5 2 No BD meds 5 16 No BD meds 5 18
*Patients on infliximab (n 5 1) and methotrexate (n 5 1) were excluded in evaluation of effect on natural killer (NK) cells due to only single
individuals in each of these subgroups. Aza 5 azathioprine; BD 5 Behçet’s disease; col 5 colchicine; MMF 5 mycophenolate mofetil;
pred 5 prednisolone; inf 5 infliximab; met 5 methotrexate; no BD meds: 5 no systemic BD-associated medication.
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The lymphocyte population was identified by assessment of
size and granularity of cells using light-scatter properties [for-
ward-scatter (FSC) versus side-scatter (SSC)] and NK per-
centage expressed as a proportion of total gated lymphocytes.
Gates were set using appropriate isotype/negative controls for
each intra- and extracellular antibody.
Degranulation assay
PBMCs were stimulated initially for 5 h in complete media
with 50 ng/ml phorbol-12-myristate-13-acetate (PMA;
Sigma) and 1 lg/ml ionomycin (Sigma) in the presence of
anti-CD107a (BioLegend) at 378C in 5% CO2. After 1 h of
stimulation, brefeldin (10 lg/ml) and monensin (2 lM)
were added and were present for the last 4 h of culture.
Cells were vortexed periodically to prevent cell settling.
PBMCs were then washed and stained for cell-surface
markers as described previously. Finally, cells were fixed
with intracellular (IC) fixation buffer (eBioscience) and
permeabilized and stained for detection of intracellular
granzyme B, as described above.
Statistical analysis
The results are expressed as mean values 6 standard error
of mean (s.e.m.). GraphPad Prism version 6 (GraphPad
Software, San Diego, CA, USA) was used for statistical
analysis. Differences between group variables were analysed
using non-parametric single and multiple comparison sta-
tistical tests where appropriate (Mann–Whitney U-test/
Kruskal–Wallis test). P-values of< 005 were considered
statistically significant. Non-parametric tests were used, as
samples were not demonstrated to be distributed normally
(Kolmogorov–Smirnov normality test). IBM SPSS Statistics
for Windows, version 22.0 (Armonk/IBM Corp., New York,
NY, USA) was used to calculate individual Pearson’s corre-
lation coefficients for each investigated predictor variable
(gender, age, BD activity and each specific BD medication)
against NK percentage. Subsequently, multivariate linear
regression analysis was performed to determine the relative
effect of each predictor variable on NK percentage using a
stepwise regression model.
Results
Peripheral blood NK cells are depleted significantly in
BD patients and correlates with disease activity
In accordance with previous literature [18], human natural
killer (NK) cells defined in this study as CD3–Vd2–CD561
lymphocytes could be separated broadly into CD56Dim and
CD56Bright subsets in all Behçet’s disease patients (BD) and
healthy controls (HC) (Fig. 1a).
NK cells expressed as a percentage of total gated
lymphocytes in the peripheral blood of all 60 BD patients
(653 6 066%) were found to be reduced significantly
compared to healthy controls (1062 6 075%) (P< 00001).
Furthermore, when the total BD cohort was subdivided based
on current disease activity, the NK percentage was reduced
significantly only in BD patients with active disease (BDActive)
(608 6 078) (P< 00001), but just failed to reach signifi-
cance in those without current signs or symptoms (BDQuiet)
(776 6 121) (P 5 00552) (Fig. 1b).
When the HC and BD cohorts were subdivided by age,
NK depletion was seen in all three age range groups when
BD patients were compared to HCs, reaching statistical sig-
nificance in the 15–34-year-old (P 5 00071) and 35–54-
year-old subgroups (P 5 00166), but just failing to show
significance in the 55–75-year-old cohort (P 5 00535).
Interestingly, ageing did not affect NK cell percentage sig-
nificantly, with no significant changes when the three age
ranges were compared in HC or BD patients (P> 005).
This suggests that BD-associated NK depletion appears to
be age-independent (Fig. 1c). Additionally, there were no
significant gender differences in NK percentage within HC
or BD cohorts or when considered together as a single
group (P> 005) (Fig. 1d).
CD56Dim and CD56Bright NK cells are decreased
significantly in the peripheral blood of BD patients
with overall proportional increase in the CD56Bright
subset
BD patients had significantly depleted CD56Dim (HC 5 999
6 074% versus BD 5 602 6 065%) (P< 00001) and
CD56Bright (HC 5 062 6 005% versus BD 5 051 6 006%)
(P 5 00015) NK subsets compared to healthy controls relative
to total lymphocytes. Overall, this led to a net increase in the
proportion of the CD56Bright subset relative to total NK cells in
BD (1280 6 182%) compared to HC (705 6 059%)
(P 5 00342) (Fig. 2a). Therefore, BD appears to be associated
with a shift in NK subsets with a relative increase in the
CD56Bright compared to CD56Dim cells on the background of
overall peripheral blood NK depletion.
CD56Dim and CD56Bright subsets are phenotypically
and functionally distinct in both HCs and BD
The expression of surface markers CD27 and CD16 as well
as the ability of NK subsets to produce IFN-g, perforin and
granzyme B and (as measured by median fluorescent inten-
sities of gated positive events) were compared in NK sub-
sets. CD56Dim NK cells were found to express 25–28 times
more surface CD16 (P< 00001) and produce significantly
higher levels of perforin (38–4 times) (P< 00001) and
granzyme B (13–15 times) (P< 005) compared to
CD56Bright cells. By contrast, the levels of CD27 surface
expression and production potential of IFN-g on a per cell
basis was not found to be different between subsets (Fig.
2b, c). These same differences were maintained in CD56Dim
and CD56Bright subsets from both HCs and BD patients,
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with no significant differences in the subsets between HCs
and BD on a per cell basis.
Increased percentage of IFN-g producing CD56Bright
cells in BD
When intracellular expression of IFN-g was analysed, the
percentage of IFN-g producing CD56Dim and CD56Bright
NK cells was higher in BD patients compared to HCs, but
this only reached statistical significance in the CD56Bright
subset (BD 4392 versus HCs 3072%) (P 5 00255) (Fig.
3a, b). By contrast, no differences in the percentage of per-
forin- and granzyme B-producing cells was observed
between HCs and BD patients in either subset, with the
majority of NK cells demonstrating a robust ability to pro-
duce these cytotoxic proteins. Furthermore, no significant
difference in IFN-g, perforin or granzyme B was observed
with respect to BD disease activity (BDquiet compared to
BDActive) (data not shown).
NK subsets show opposing trends in percentage of
CD56Dim and CD56Bright cells expressing CD27 and
CD16
The percentage of CD56Bright NK cells expressing CD16
was significantly higher in BD patients (3714 6 147%)
when compared with HC (2540 6 145%) (P< 00001)
(Fig. 3b). This was in direct contrast to the CD56Dim subset
which, although this had a higher and predominant expres-
sion of surface CD16, showed a significant decrease in sur-
face expression in BD (8610 6 209%) compared to HCs
(9354 6 087%) (P 5 00032) (Fig. 3a). However, the
opposite pattern of change was observed in CD27 expres-
sion where the percentage of CD56Dim subset expressing
CD27 was increased in BD (760 6 064%) compared to
HCs (458 6 033%) (Fig. 3a). In contrast, the CD56Bright
subset showed the opposite trend (BD 3586 versus HCs
3950%), which failed to reach statistical significance
























































































Fig. 1. Natural killer (NK) cell peripheral blood percentage decreases independently of age in Behçet’s disease (BD)Active patients. (a) NK cells are
defined using flow cytometry as CD56(1) CD3(–), with two main subsets characterized by intensity of CD56 expression CD56Bright and CD56Dim
(dot-plot shown from a single healthy control sample to demonstrate population gating). (b) NK cells CD561CD3– are expressed as a
proportion of total gated lymphocytes in healthy controls (HC) (n 5 60) compared to BD patients with no clinical signs of activity BDQuiet
(n 5 16) and those with active systems BDActive patients (n 5 44) (total BD; n 5 60). (c) NK/gated lymphocyte (%) is compared in both total
BD and HC patients across age ranges 15–34, 35–54 and 55–75 years. CD56Bright NK cells expressed as a proportion of total NK cells is
compared between HC and BD patients. (d) Gender differences in NK/gated lymphocyte (%) is compared between HC and BD patients.
*P< 005; **P< 001; ***P< 0001; n.s. 5 not significant. Numbers in parentheses above each bar indicate number of individuals in each
comparison group.
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Increased percentage of NK cells with degranulation
potential in BD patients compared to HC
individuals
Total NK cells exhibited higher overall percentage expres-
sion of the degranulation marker CD107a following activa-
tion in BD compared to HC individuals (P 5 0026) (Fig.
3c), with no significant further increase in BDActive com-
pared to BDQuiet patients (P> 005). However, when NK
subsets were compared on a per cell basis, CD56Bright subset
expressed significantly higher levels of CD107a compared
to the CD56Dim subset within both the HC and BD groups
(P< 001). Overall, the CD107a expression on a per cell
basis was similar in both NK subsets between HC and BD
patients (P> 005) (Fig. 3d).
NK depletion is greatest in BD patients on current
azathioprine therapy
In order to determine whether NK cell depletion was due
to disease activity or as a result of specific immunomodula-
tory medication, the BD cohort was subdivided according
to current systemic BD drug therapy (azathioprine, colchi-
cine, prednisolone and mycophenolate mofetil). The effect
of these medications (when used as single/monotherapy)
on NK percentage was compared with both HCs and non-
medicated BD patients (Fig. 4a).
NK cells/total lymphocytes (%) were reduced signifi-
cantly only in azathioprine-treated BD patients compared
to HCs (P< 001) but, interestingly, not for BD patients on
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Fig. 2. CD56Dim and CD56Bright natural killer (NK) subsets are phenotypically and functionally distinct. (a) Difference in percentage of CD56Dim
(far left) and CD56Bright subsets (middle) as a percentage of gated lymphocytes with change in CD56Bright subset expressed as a percentage of
total NK cells (far right). (b) Flow cytometry histogram plots showing intensity of surface marker expression of CD27 and CD16 and
intracellular cytokine staining for interferon (IFN)-g, perforin and granzyme B following 5-h phorbol myristate actate (PMA)/ionomycin
stimulation (representative plots from healthy control sample are shown). (c) Summary median fluorescent intensities (MFI) of gated positive
events for CD27, CD16, IFN-g, perforin and granzyme B showing relative differences in expression intensities of markers on each of NK subset
(CD56Dim and CD56Bright) in healthy controls (HC) and in Behçet’s disease (BD) patients. *P< 005; **P< 001; ***P< 0001; n.s. 5 not
significant.
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Importantly, BD patients not currently receiving active
drug therapy (BDNo therapy) also demonstrated reduced per-
centages of NK cells in comparison with HCs (P< 005)
(Fig. 4a).
Furthermore, when BD patients were subgrouped
according to both disease activity (BDQuiet/BDActive) and
whether or not they were taking azathioprine (BDAza/
BDNon-Aza), it was apparent that the two groups with the
lowest NK percentages were both currently taking azathio-
prine (BDAza/Quiet and BDAza/Active) (Fig. 4b). However,
BDNon-AZA/Active patients also showed significantly depleted
percentages of NK cells compared to HCs (Fig. 4b).
We further investigated the relative importance of the
following predictor variables (gender, age, BD activity and
BD medication) in relation to peripheral blood NK per-
centage by initially examining the Pearson correlation coef-
ficients of each predictor variable against NK percentage.
This revealed BD activity, azathioprine therapy and gender
to be correlated significantly with NK percentage (P
< 005) (Table 2). However, when stepwise multivariate
linear regression was used to generate the regression model,
only BD activity and azathioprine therapy were determined
as having significant depletive effects on the NK cell per-
centage from the variables analysed (P < 005) (Table 2). It
appears that both the systemic BD activity and azathio-
prine medication seem to have independent depletive
effects on peripheral blood NK cells. However, although
statistically significant, the regression model incorporating
these two variables together only explained 152% of the
variation on NK percentage (R2 5 0152, P< 0001***).
Discussion
This current cross-sectional experimental study represents
the largest study to date investigating NK cells, their subsets
and function in relation to BD systemic clinical activity
and common BD medication. While a number of previous
studies have investigated NK cells in BD patients [14,32],
the literature is somewhat contradictory, due probably to


















































































































































































































































































Fig. 3. Comparison of percentage expression of CD27, CD16 and interferon (IFN)-g between natural killer (NK)Dim and NKBright subsets.
Percentage expression of surface markers CD27 and CD16 alongside intracellular staining for the cytokine IFN-g and cytotoxic proteins perforin
and granzyme B following 5-h phorbol myristate acetate (PMA)/ionomycin stimulation for (a) CD56Dim and (b) CD56Bright NK subsets. (c)
Percentage CD107a expression is shown on total NK cells in heathy control (HC) individuals (n 5 6) compared to Behçet’s disease (BD) patients
(n 5 14) following 5-h PMA/ionomycin activation (left panel). Summary median fluorescent intensities (MFI) of gated positive events are
shown for CD107a showing relative differences in expression intensities of markers on each of NK subset (CD56Dim and CD56Bright) in HC and
in BD patients. *P< 005; **P< 001; ***P< 0001; n.s. 5 not significant.
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ethnicity and varied clinical presentation overlaid with an
often-complex drug management regimen. This unclear
picture is reflected in the findings of previous studies that
both support [35] and contradict [14,32] NK cell periph-
eral blood depletion and activity in BD.
In this study, both CD56Dim and CD56Bright NK cells
were found to be depleted within the peripheral blood
compartment of BD patients compared to healthy controls.
Indeed, NK cell depletion was not only associated with
patients diagnosed with BD but, interestingly, was more
marked in patients with current disease activity (BDActive)
compared to those diagnosed previously with BD but with-
out current active disease (BDQuiet). Overall, there was
depletion of both CD56Dim and CD56Bright NK subsets,
with a proportionately greater loss of the CD56Dim subset
resulting in an overall increase in the proportion of
CD56Bright cells relative to the total NK population.
NK cell depletion also appeared to be most marked in
BD patients taking azathioprine compared to those on
non-azathioprine BD medication. This finding is sup-
ported by a number of other studies that observed NK
depletion and reduced NK activity following azathioprine
therapy for rheumatoid arthritis [42], inflammatory bowel
disease [43] and in systemic lupus erythematosus [44].
Therefore, it is apparent from this study that both disease






































































































Fig. 4. Natural killer (NK) cell peripheral blood percentage is reduced significantly in patients under azathioprine therapy. (a) NK cells expressed
as a percentage of total gated lymphocytes was compared in patients on different forms of Behçet’s disease (BD) medication; colchicine (BDCol),
prednisolone (BDPred), mycophenolate mofetil (BDMMF) and azathioprine (BDAza) and compared to healthy controls (HC) as well as patients not
currently taking BD-associated medication (BDNo therapy). (b) NK cell percentage expressed as a percentage of total lymphocytes in BD patients
subgrouped according to disease activity (BDQuiet/Active) and whether currently taking azathioprine or not (BDAza or BDNon-Aza). *P< 005;
**P< 0001; ***P< 0001. Aza 5 azathioprine; Col 5 colchicine; MMF 5 mycophenolate mofetil; Pred 5 prednisolone; Inf 5 infliximab;
Met 5 methotrexate; no BD meds 5 no systemic BD-associated medication. Patients on infliximab (n 5 1) and methotrexate (n 5 1) were
excluded in evaluation of effect on NK cells due to only single individuals in each of these subgroups. Numbers in parentheses above each bar
indicate number of individuals in each comparison group.
Table 2. Bivariate and multivariate linear regression investigating the relationship between various predictor variables and natural killer (NK) cell
percentage
Correlation Multiple linear regression
Variable Pearson P-value b-coefficient 95% CI P-value
Gender 20203 0013*
Age 20070 0225
BD activity 20352 <0001*** 23070 25275 to 20864 **0007




Individual Pearson’s correlation coefficient statistics with associated P-values for each independent predictor variable of NK cell percentage
alongside stepwise multiple linear regression model (R2 5 0152, F(2, 117) 5 10511, P 5 0000063 (P< 0001***). BD 5 Behçet’s disease;
CI 5 confidence interval; MMF 5 mycophenolate mofetil.
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independent depletive effect on NK cells, which was con-
firmed by multivariate analysis. Azathioprine, a purine
analogue, is thought to work by blocking the de-novo path-
way of purine synthesis which contributes to its relative
specificity to lymphocytes [45]. It has also been shown that
azathioprine inhibits proliferation in resting or newly acti-
vated cells but not pre-activated cells through an increase
in apoptosis [46]. Therefore, if a BD patient has experi-
enced an event that triggers relapse, azathioprine would
then eliminate newly activated cells. The cells that were
already activated will not be affected by azathioprine and
might be leaving the circulation for trafficking into the tis-
sues. While azathioprine inhibits cell proliferation, colchi-
cine acts primarily by inhibiting microtubule
polymerization, which results in decreased cytokine secre-
tion and migration [47]. Interestingly, reduced NK activity
has also been observed in mycophenolate mofetil (MMF)
therapy [48] as well as in patients on prednisolone therapy
in previous studies, but was not observed within this
cohort [49]. Prednisolone, a synthetic glucocorticoid, inter-
feres primarily with the cellular components of the micro-
circulation following an inflammatory response. This
results in decreased vasodilatation, vascular permeability
and suppression of leucocyte emigration [50]. Similarly,
MMF is thought to supress recruitment to inflammatory
sites by inhibiting glycosylation of adhesion molecules,
which in this case might maintain the circulating pool of
NK cells rather than allow them to migrate to inflamed tis-
sues [51].
NK cell peripheral blood depletion in BD pathology
therefore suggests different possibilities in terms of mecha-
nistic explanation. One possibility is that BD directly causes
NK cell depletion due to net trafficking from peripheral
blood into disease active tissue sites, and that BD activity
might correlate with an overall net loss of NK cells from
the peripheral blood compartment. This perhaps mirrors
other immunological NK-associated diseases such as psori-
asis [52], rheumatoid arthritis (RA) [53] and type 1 diabe-
tes mellitus (T1DM) [54], where this has similarly been
observed. Indeed, there is further supporting evidence for
NK tissue trafficking in active BD, with NK cells present in
histological BD samples in eye lesions (uveitis) [55], oral
aphthous ulcers and erythema nodosum [14]. An alterna-
tive possibility is that NK cells are depleted in both periph-
eral blood as well as in tissue sites as a direct consequence
of BD pathology, conceivably leaving individuals suscepti-
ble to chronic viral infections, a commonly hypothesized
environmental trigger of BD. We have confirmed that
depletion of NK cells, both in their number and function,
occurs in the BD patients. This may be a result of the
underlying immune-pathogenic process and/or consequen-
ces of azathioprine therapy in BD.
As mentioned previously, viral infectious agents such as
herpes simplex virus (HSV) and Epstein–Barr virus (EBV)
have been suggested as possible environmental triggers of
BD [6,7]. Therefore, it follows that the protective response
from anti-viral immune cells such as NK cells may play a
key role in regulating BD activity. Indeed, the pathological
and immunological consequences of NK cell depletion has
been studied in both animal and human studies, highlight-
ing the key role NK cells play in anti-viral immunity
[56,57]. While NK cells have an obvious role in the direct
lysis of virally infected cells, they also indirectly play a key
role in immunoregulating and dampening down anti-viral
CD41 and CD81 T cell responses [58,59]. In addition, NK
cells have also been shown capable of careful regulation of
T cell subpopulation specifically controlling Th1/Treg as
well as the Th17/Treg balance in one infection model [60].
Therefore, it is apparent that NK cells are not only impor-
tant in direct anti-viral responses; they are also key regula-
tory cells in controlling acquired specific immune
responses during viral infection and consequently may be
key cells in having a role in controlling BD activity.
NK depletion in BD was accompanied by a reduction in
the percentage of cells expressing CD16 and an increase in
CD27 percentage expression within the predominant
CD56Dim NK subset. In contrast, CD161CD56Bright NK
cells were increased in BD, suggesting the potential for
either direct lysis or antibody-dependent cell-mediated
cytotoxicity (ADCC) killing by this subset, which has been
shown to be an intermediate stage of NK cell differentia-
tion [61]. Additionally, the percentage of CD56Bright NK
cells with IFN-g production potential increased in BD
patients, which supports previous evidence indicating a
role for NK cells in Th1 cytokine production in BD [13].
Indeed, the switch to increased IFN-g production is also
seen in conventional CD41 T cells in active BD [13,62,63].
However, on a per cell basis we did not observe signifi-
cantly increased IFN-g production by the CD56Bright sub-
set, as has been observed in other studies [20,21].
This study also supports the conventional literature that
stimulated CD56Dim NK cells produce higher levels of cyto-
toxic mediators (i.e. perforin and granzyme B) and express
significantly more CD16 compared to CD56Bright cells.
However, while appearing to have greater ability to produce
more intracellular perforin and granzyme B, the degranula-
tion potential (CD107a expression) of this CD56Dim subset
was reduced compared to CD56Bright cells. Indeed, this
inverse relationship between levels of intracellular cytotoxic
protein and CD107a expression have been observed previ-
ously when cytotoxic lymphocytes are activated with phor-
bol myristate acetate (PMA) and ionomycin [64]. This
observation may simply reflect differences in granule
release kinetics during the 5 h of stimulation, inherent dif-
ferences in granule CD107a receptor density or rate of
internalization of the marker. Finally, when NK cells were
considered as a single population, the percentage CD107a
expression was found to be significantly higher in BD
patients compared to HC individuals, suggesting that NK
cells are inherently more cytotoxic in BD compared to
NK cells in Behçet’s disease
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health. As mentioned previously, CD107a has been shown
to be a more sensitive marker of NK activity when com-
pared to intracellular cytokine and chromium release
assays, and so may represent the most important functional
cytotoxic marker [28].
In summary, this present study suggests that both
CD56Dim and CD56Bright subsets are depleted in the periph-
eral blood of BD patients and that depletion is more marked
in patients with active disease as well as in BD patients tak-
ing azathioprine. NK peripheral blood depletion in BD
patients therefore may reflect an increased homing of these
cytotoxic cells to sites of inflammation in active BD initiat-
ing and maintaining tissue inflammation through produc-
tion of Th1 cytokines and cytotoxic mediators.
Further studies are clearly required to better understand
the mechanism of NK depletion in BD patients and the rel-
ative influence of disease activity and azathioprine medica-
tion on NK cells within the peripheral blood as well as in
the disease affected tissues.
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